Diabesity Rounds

Weekly ribupatide lowers body weight over 48 weeks in Chinese adults without diabetes

In the phase 3 GEMINI-1 trial, once-weekly ribupatide reduced body weight by 10.7% to 17.7% at week 48, against 1.4% with placebo, with gastrointestinal events, mostly mild to moderate, as the most frequent adverse effects.

At a glance

  • Phase 3 trial of 567 adults in China with overweight or obesity and no diabetes, randomised to ribupatide 2, 4 or 6 mg or placebo for 48 weeks.
  • Least-squares mean body weight fell by 10.7%, 16.4% and 17.7% with the three doses, against 1.4% with placebo (P < .001 for all placebo-adjusted differences).
  • Gastrointestinal events were the most frequent adverse events; 0.7% of participants permanently stopped treatment because of adverse events.

Key result

All three ribupatide doses lowered body weight more than placebo at week 48.

Percent change in body weight, Week 48

ribupatide 2 mg−10.7%
ribupatide 4 mg−16.4%
ribupatide 6 mg−17.7%
placebo−1.4%

567 participants · 48 weeks · P < .001 for all

Numbers as reported in the source.

The study

GEMINI-1 was a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial run at 55 sites in China and published in JAMA. It tested ribupatide, a once-weekly subcutaneous dual GIP/GLP-1 receptor agonist, for weight loss.

Adults without diabetes were enrolled from May to June 2024 if they had a body mass index (BMI) of 28 or greater, or of 24 or greater with at least 1 weight-related comorbidity. They were randomised to ribupatide (target doses of 2 mg, 4 mg or 6 mg) or matching placebo for 48 weeks. The dose was escalated over up to 20 weeks, and all groups also received lifestyle intervention. Final follow-up was on June 20, 2025.

The primary outcome was change in body weight from baseline to week 48, including percent change and the share of participants losing at least 5% of body weight, analysed under the treatment policy estimand.

What they found

Of 567 participants, 309 (54.5%) were female. Mean age was 34.4 years, mean body weight was 93.0 kg and mean BMI was 33.3. In all, 514 (90.7%) completed the 48-week treatment period.

At week 48, the least-squares mean change in body weight was a fall of 10.7%, 16.4% and 17.7% with ribupatide 2, 4 and 6 mg, against 1.4% with placebo. The placebo-adjusted differences were -9.3 percentage points (95% CI, -11.4 to -7.3) with 2 mg, -15.0 (95% CI, -17.1 to -12.9) with 4 mg and -16.3 (95% CI, -18.4 to -14.2) with 6 mg. All were statistically significant (P < .001).

The multiply imputed response rates for at least 5% weight reduction were 68.1% on 2 mg, 88.0% on 4 mg, 85.7% on 6 mg and 16.0% on placebo. The placebo-adjusted differences were 52.0, 72.0 and 69.7 percentage points (all P < .001).

Gastrointestinal events were the most frequent adverse events. They occurred in 47.9%, 58.2% and 63.1% of participants on 2, 4 and 6 mg, against 23.1% on placebo. Most were mild to moderate, and 0.7% of participants permanently stopped study treatment because of adverse events.

How much weight to give it

This is a randomised, double-blind, placebo-controlled phase 3 trial in which 90.7% completed treatment, so the main weight result is strong evidence for this population. The authors conclude that ribupatide resulted in significantly greater weight loss at 48 weeks.

Some limits matter. All participants were adults in China without diabetes. They were relatively young, with a mean age of 34.4 years, so how the results apply to older adults is uncertain, and people with diabetes were not studied. The outcomes are body weight measures; the abstract does not report effects on heart, kidney or other hard outcomes. The treatment period and primary outcome were at 48 weeks, so effects beyond that are not reported in the abstract. The abstract does not report a formal comparison between the 4 mg and 6 mg doses, and it does not report funding.

For your clinic

The abstract gives no information on its regulatory status in India. Doctors counselling patients about newer weight-loss injections can note that gastrointestinal events were common and numerically more frequent at higher doses (47.9%, 58.2% and 63.1% vs 23.1% with placebo), and 0.7% of participants permanently stopped study treatment because of adverse events. Read the full paper for detailed safety data, the dose-escalation schedule and the lifestyle programme before drawing conclusions.

Source

Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial.

Zhao L, Chen Y, Cheng Z et al.. JAMA. 15 November 2026

Read the source · DOI 10.1001/jama.2026.24796

Teaching a session? Download this report as a slide (PNG, free to use with credit).

For registered medical practitioners. This report summarises published research and is not advice for individual patients. Read the full paper and current guidelines before changing practice. Found an error? Write to editor@diabesityrounds.com; see our corrections and editorial policy.

More on glp-1 and incretin drugs

Go deeper